Biological markers for breast carcinoma.

Area of Science:

• Oncology
• Biochemistry

Background:

• Intense research for breast carcinoma biological markers over the last decade.
• Existing markers in body fluids lack specificity and sensitivity for early detection or low tumor burden assessment.
• Biological variations can complicate marker data interpretation.

Purpose of the Study:

• To review the current status of biological markers for breast cancer.
• To evaluate the utility of plasma carcinoembryonic antigen (CEA) in breast cancer management.
• To highlight promising future research directions for breast cancer marker discovery.

Main Methods:

• Review of existing literature on breast cancer biomarkers.
• Analysis of the evaluation and clinical application of plasma carcinoembryonic antigen (CEA).
• Discussion of emerging techniques, including monoclonal antibody-based marker identification.

Main Results:

• Plasma CEA is elevated in 60%-70% of metastatic breast cancer patients, with levels often proportional to tumor burden.
• Changes in CEA levels correlate with treatment response and disease progression.
• Serial CEA measurements post-mastectomy may aid in predicting recurrence risk.

Conclusions:

• Plasma CEA is a valuable tool for monitoring metastatic breast cancer and predicting recurrence.
• A highly specific and sensitive biomarker for early breast cancer detection is still needed.
• Monoclonal antibody techniques offer a promising avenue for discovering novel, specific breast cancer markers.